Grace Therapeutics, Inc. (GRCE) Key Metrics
GRCE valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $39.8M
- Enterprise value
- $31.1M
- P/E (TTM)
- —
- Forward P/E
- 2.2
- PEG ratio
- —
- Price / sales
- 197.7
- Price / book
- 0.9 10-yr median 0.4
- EV / EBITDA
- 19.6
- Dividend yield
- —
- Beta
- 0.33
GRCE key metrics, FY2017–FY2026
Fiscal year ended March 31, 2026 · U.S. dollarsGRCE valuation Price multiples at each fiscal year-end price.
Price / book+189.2%
1.2
FY2026 · hover or tap a bar for each year
FY2017FY2026
Free cash flow yield+42.5 pts
−11.6%
FY2026 · hover or tap a bar for each year
FY2017FY2026
GRCE returns How much profit the business earns on the capital it uses.
Return on equity+9.3 pts
−11.9%
FY2026 · hover or tap a bar for each year
FY2017FY2026
Return on invested capital+25.9 pts
−19.1%
FY2026 · hover or tap a bar for each year
FY2017FY2026
Return on assets+7.5 pts
−11.2%
FY2026 · hover or tap a bar for each year
FY2017FY2026
Asset turnover
0.00
FY2026 · hover or tap a bar for each year
FY2017FY2026
GRCE per-share figures Results divided by the shares outstanding at year-end.
Revenue per share
$0.00
FY2026 · hover or tap a bar for each year
FY2017FY2026
Earnings per share
−$0.47
FY2026 · hover or tap a bar for each year
FY2017FY2026
Free cash flow per share
−$0.54
FY2026 · hover or tap a bar for each year
FY2017FY2026
Book value per share−29.8%
$3.87
FY2026 · hover or tap a bar for each year
FY2017FY2026
Shares outstanding+36.6%
16.5M
FY2026 · hover or tap a bar for each year
FY2017FY2026
GRCE financial health Debt, liquidity and how easily interest is covered.
Net debt+$5.2M
−$17.0M
FY2026 · hover or tap a bar for each year
FY2017FY2026
Current ratio−31.2%
8.10
FY2026 · hover or tap a bar for each year
FY2017FY2026
GRCE efficiency & capital use Working capital cycle and where the cash goes.
Days payables outstanding−7,947 days
33,976 days
FY2026 · hover or tap a bar for each year
FY2017FY2026
GRCE valuation history
Fiscal year-endToday10-year median
GRCE returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
GRCE debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
GRCE cash returned to shareholders
DividendsBuybacksFree cash flow
GRCE price vs earnings per share
Share price at year-endEPS (right axis)
GRCE key metrics
FY2017–FY2026| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $76.4M | $27.6M | $32.7M | $20.5M | $44.9M | — | — | — | — | — |
| Enterprise value | $59.5M | $5.4M | $9.7M | −$6.9M | $1.6M | — | — | — | — | — |
| Price / book | 1.2 | 0.4 | 0.5 | 0.3 | 0.4 | — | — | — | — | — |
| Earnings yield | −10.2% | −49.4% | −53.4% | −279.6% | −27.3% | — | — | — | — | — |
| Free cash flow yield | −11.6% | −54.1% | −37.8% | −77.6% | −38.3% | — | — | — | — | — |
| Share price at fiscal year-end | $4.63 | $2.28 | $3.43 | $2.76 | $7.32 | $28.80 | $18.24 | $48.96 | $48.96 | $65.28 |
| Per share | ||||||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — |
| Earnings per share | −$0.47 | −$1.13 | −$1.83 | −$7.72 | −$2.00 | — | — | — | — | — |
| Operating cash flow per share | −$0.54 | −$1.23 | −$1.29 | −$2.14 | −$2.81 | — | — | — | — | — |
| Free cash flow per share | −$0.54 | −$1.23 | −$1.30 | −$2.14 | −$2.81 | — | — | — | — | — |
| Cash per share | $1.03 | $1.83 | $2.41 | $3.75 | $7.11 | — | — | — | — | — |
| Book value per share | $3.87 | $5.51 | $6.48 | $9.14 | $17.63 | — | — | — | — | — |
| Tangible book value per share | $0.89 | $1.43 | $1.31 | $2.51 | $4.15 | — | — | — | — | — |
| Capex per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — |
| Debt per share | — | — | — | $0.07 | $0.05 | — | — | — | — | — |
| Shares outstanding | 16.5M | 12.1M | 9.5M | 7.4M | 6.1M | — | — | — | — | — |
| Change in shares outstanding | +36.6% | +26.8% | +28.2% | +21.1% | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −11.9% | −21.2% | −26.9% | −65.1% | −13.8% | −70.3% | −346.6% | −452.1% | −118.6% | −50.5% |
| Return on invested capital (ROIC) | −19.1% | −45.1% | −34.8% | −105.7% | −52.5% | — | — | — | −165.1% | −64.7% |
| Return on assets (ROA) | −11.2% | −18.8% | −22.9% | −55.2% | −11.8% | −56.1% | −147.3% | −144.0% | −77.0% | −45.4% |
| Return on tangible assets | −44.8% | −60.0% | −72.6% | −192.2% | −26.8% | −39.6% | −193.8% | −129.0% | −166.8% | −80.7% |
| Financial health | ||||||||||
| Total debt | — | — | — | $485,000 | $295,000 | $108,037 | $207,795 | $1.4M | $1.2M | $1.4M |
| Cash & short-term investments | $17.0M | $22.1M | $23.0M | $27.9M | $43.7M | $76.3M | $20.1M | $25.8M | $6.4M | $9.8M |
| Net debt | −$17.0M | −$22.1M | −$23.0M | −$27.4M | −$43.4M | −$76.2M | −$19.9M | −$24.4M | −$5.1M | −$8.4M |
| Debt / equity | — | — | — | 0.01 | 0.00 | 0.00 | 0.01 | 0.12 | 0.20 | 0.06 |
| Debt / assets | — | — | — | 0.01 | 0.00 | 0.00 | 0.01 | 0.04 | 0.07 | 0.06 |
| Current ratio | 8.10 | 11.77 | 14.26 | 8.59 | 13.97 | 39.50 | 2.16 | 2.05 | 1.42 | 4.76 |
| Quick ratio | 8.10 | 11.77 | 14.26 | 8.59 | 13.97 | 39.50 | 2.16 | 2.05 | 1.42 | 4.76 |
| Interest coverage | — | — | — | — | — | -78.1 | -117.9 | -32.7 | -41.0 | -193.3 |
| Working capital | $15.2M | $20.8M | $22.3M | $25.9M | $42.3M | $76.4M | $12.1M | $14.3M | $2.2M | $8.1M |
| Invested capital | $46.9M | $44.5M | $38.7M | $40.5M | $64.9M | −$6.3M | −$1.6M | −$13.4M | $1.2M | $13.3M |
| Tangible asset value | $14.6M | $17.3M | $12.5M | $18.7M | $25.5M | $69.9M | $12.4M | $4.7M | −$1.4M | $9.3M |
| Net current asset value | $14.6M | $17.3M | $12.5M | $18.1M | $25.2M | $69.8M | $8.6M | $2.1M | −$4.1M | $6.4M |
| Graham net-net per share | $0.86 | $1.39 | $1.26 | $2.33 | $3.86 | — | — | — | — | — |
| Capital allocation | ||||||||||
| Share buybacks (net) | — | — | — | — | — | — | — | — | $30,973 | — |
| Capex / revenue | — | — | — | — | — | 28.0% | — | — | — | — |
| Capex / depreciation | 0.00 | 0.00 | 2.00 | 0.14 | — | 0.07 | 0.14 | 0.23 | 0.17 | 1.00 |
| Stock-based compensation / revenue | — | — | — | — | — | 476.8% | — | — | — | — |
| R&D / revenue | — | — | — | — | — | 2,129.1% | — | — | — | — |
| SG&A / revenue | — | — | — | — | — | 3,395.4% | — | — | — | — |
| Efficiency | ||||||||||
| Days sales outstanding | — | — | — | — | — | 848.2 | — | — | — | — |
| Days of inventory on hand | — | — | — | — | — | — | — | — | 0.0 | — |
| Days payables outstanding | 33,975.9 | 41,922.9 | 37,313.0 | 6,472.9 | — | 3,904.4 | — | 332.9 | 360.2 | — |
| Cash conversion cycle (days) | — | — | — | — | — | -3,056.1 | — | — | — | — |
| Receivables turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.43 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables turnover | 0.01 | 0.01 | 0.01 | 0.06 | 0.00 | 0.09 | — | 1.10 | 1.01 | — |
| Inventory turnover | — | — | — | — | — | — | — | — | 2,683,720.00 | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $73,000 | $424,000 | $762,000 | $675,000 | $606,905 | $718,810 | $1.2M | $1.2M | $482,714 | $250,304 |
| Average payables | $651,500 | $804,000 | $1.1M | $2.2M | $1.7M | $1.3M | $2.7M | $2.8M | $2.6M | — |
| Average inventory | — | — | — | — | — | — | — | — | $1 | — |
| Intangibles / total assets | 73.9% | 68.4% | 67.2% | 62.3% | 64.4% | 0.0% | 18.6% | 17.3% | 43.8% | 48.7% |
Computed from GRCE's annual financial statements (latest annual report filed June 18, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
GRCE valuation and financial ratios
Grace Therapeutics earned a return on equity of −11.9% and a return on invested capital of −19.1% in fiscal 2026.
See the GRCE income statement, the GRCE chart for price history, or the GRCE stock overview for the latest quote and news.
GRCE key metrics FAQ
What is Grace Therapeutics's return on equity?
Grace Therapeutics's return on equity (ROE) was −11.9% in fiscal 2026: net income of -$7.8 million on average shareholders' equity of $65.3 million.
What is Grace Therapeutics's ROIC?
Grace Therapeutics's return on invested capital was −19.1% in fiscal 2026, using after-tax operating income divided by average debt plus equity minus cash.
What is Grace Therapeutics's free cash flow yield?
Grace Therapeutics generated -$8.9 million of free cash flow in fiscal 2026, a free cash flow yield of −11.6% on its market value at year-end ($76.4 million).
What is Grace Therapeutics's current ratio?
Grace Therapeutics's current ratio was 8.10 at the end of fiscal 2026: current assets were 8.10 times current liabilities.